Clinical Trial Update: A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating safety, pharmacokinetics, and efficacy of crovalimab versus eculizumab in participants with paroxysmal nocturnal hemoglobinuria …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Nocturnal Hemoglobinuria

Drugs mentioned

• Crovalimab (crovalimab)
• Eculizumab (eculizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | Status: ACTIVE_NOT_RECRUITING